{"id":"NCT00315445","sponsor":"Purdue Pharma LP","briefTitle":"The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.","officialTitle":"A Comparative Study of Buprenorphine TDS, Oxycodone/ Acetaminophen Tablets Qid and Placebo in Patients With Chronic Back Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1997-12","primaryCompletion":"1998-05","completion":"1998-05","firstPosted":"2006-04-18","resultsPosted":"2011-08-10","lastUpdate":"2012-09-03"},"enrollment":134,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Back Pain"],"interventions":[{"type":"DRUG","name":"Buprenorphine transdermal patch","otherNames":["Butransâ„¢"]},{"type":"DRUG","name":"Placebo oxycodone/acetaminophen tablets","otherNames":[]},{"type":"DRUG","name":"OXY/APAP","otherNames":[]},{"type":"DRUG","name":"Placebo transdermal patch (TDS)","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"OXY/APAP","type":"ACTIVE_COMPARATOR"},{"label":"BTDS","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to assess the safety of the buprenorphine transdermal system (5, 10, and 20) in comparison to placebo transdermal system and immediate release oxycodone/ acetaminophen in subjects with chronic back pain. The double-blind treatment intervention duration is 84 days during which time supplemental analgesic medication (non-steroidal anti-inflammatory drugs) will be allowed for all subjects in addition to study drug.","primaryOutcome":{"measure":"Pain on the Average, Mean Change From Baseline Days 21-84 (Last Observation Carried Forward [LOCF])","timeFrame":"On baseline day 1 and days 21, 30, 45, 60, 75, and 84, and, if applicable, at early termination.","effectByArm":[{"arm":"Placebo","deltaMin":-1.01,"sd":0.37},{"arm":"OXY/APAP","deltaMin":-1.82,"sd":0.36},{"arm":"BTDS","deltaMin":-1.92,"sd":0.34}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0350"},{"comp":"OG000 vs OG001","p":"0.0624"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":45},"commonTop":["Nausea","Dizziness","Somnolence","Constipation","Headache"]}}